A practical reference on synthetic peptide: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-21. Anything still debated is marked as such rather than presented as settled.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Hereditary or acquired defects of VWF lead to von Willebrand disease (vWD), a bleeding diathesis of the skin and mucous membranes, causing nosebleeds, menorrhagia, and gastrointestinal bleeding. The point at which the mutation occurs determines the severity of the bleeding diathesis. There are three types (I, II and III), and type II is further divided in several subtypes. Treatment depends on the nature of the abnormality and the severity of the symptoms. Most cases of vWD are hereditary, but abnormalities of VWF may be acquired; aortic valve stenosis, for instance, has been linked to vWD type IIA, causing gastrointestinal bleeding - an association known as Heyde's syndrome. In thrombotic thrombocytopenic purpura (TTP) and hemolytic–uremic syndrome (HUS), ADAMTS13 either is deficient or has been inhibited by antibodies directed at the enzyme. This leads to decreased breakdown of the ultra-large multimers of VWF and microangiopathic hemolytic anemia with deposition of fibrin and platelets in small vessels, and capillary necrosis. In TTP, the organ most obviously affected is the brain; in HUS, the kidney. Higher levels of VWF are more common among people that have had ischemic stroke (from blood-clotting) for the first time. Occurrence is not affected by ADAMTS13, and the only significant genetic factor is the person's blood group. High plasma VWF levels were found to be an independent predictor of major bleeding in anticoagulated atrial fibrillation patients.
Further separation was carried out in the presence of a citric acid/ammonium buffer solution in a weakly acidic medium (pH ≈ 3.5), using ion exchange at elevated temperature. The chromatographic separation behavior was unknown for element 97 at the time but was anticipated by analogy with terbium. The first results were disappointing because no alpha-particle emission signature could be detected from the elution product. With further analysis, searching for characteristic X-rays and conversion electron signals, a berkelium isotope was eventually detected. Its mass number was uncertain between 243 and 244 in the initial report, but was later established as 243.
=== Polymerization === The ring-opening polymerization of butyrolactone gives polybutyrolactone. The resulting reverts to the monomer by thermal cracking. It is claimed that poly(GBL) is competitive with commercial biomaterial poly(4-hydroxybutyrate), or P4HB. It is further claimed that poly(GBL) is cheaper to make than P4HB, although both are bio-derived.
Mogo the Living Planet is a superhero appearing in American comic books by DC Comics. Mogo is a sentient planet, and as a member of the interplanetary police force known as the Green Lantern Corps, appears as a supporting character in storylines featuring that group, specifically the Green Lantern franchise. Created by writer Alan Moore and writer Dave Gibbons, Mogo first appeared in Green Lantern (vol. 2) #188 (May 1985) in a story titled "Mogo Doesn't Socialize".
Diallyl disulfide (DADS or 4,5-dithia-1,7-octadiene) is an organosulfur compound derived from garlic and a few other plants in the genus Allium. Along with diallyl trisulfide and diallyl tetrasulfide, it is one of the principal components of the distilled oil of garlic. It is a yellowish liquid which is insoluble in water and has a strong garlic odor. It is produced during the decomposition of allicin, which is released upon crushing garlic and other plants of the family Alliaceae. Diallyl disulfide has many of the health benefits of garlic, but it is also an allergen causing garlic allergy. Highly diluted, it is used as a flavoring in food. It decomposes in the human body into other compounds such as allyl methyl sulfide.
Sources: en.wikipedia.org
=== European Union === In November, Castillo met with Josep Borrell, high representative of the European Union (EU), where Castillo highlighted the solid relationship between Peru and the EU, expressing his "firm will not only to deepen our ties with the European Union, but also to attract European investment for the development of Peru's immense potential". Borrell, meanwhile, expressed the EU's support for Castillo's legitimacy. In October 2022, the Peruvian foreign minister signed in Brussels an EU-Peru Memorandum of Understanding and a Framework Participation Agreement for Peru's participation in crisis management missions and operations, whether military or civilian, organized by the EU. In this way, the Peruvian armed forces and the police would participate voluntarily in such EU operations. In addition, the EU announced a contribution of 14 million euros to Peru for the ecological transition of the Andean country.
C-4 or Composition C-4 is a common variety of the plastic explosive family known as Composition C, which uses RDX as its explosive agent. C-4 is composed of explosives, plastic binder, plasticizer to make it malleable, and usually a marker or odorizing taggant chemical. C-4 has a texture similar to modelling clay and can be molded into any desired shape. C-4 is relatively insensitive and can be detonated only by the shock wave from a detonator or blasting cap. A similar British plastic explosive, also based on RDX but with a plasticizer different from that used in Composition C-4, is known as PE-4 (Plastic Explosive No. 4).
=== Pharmacodynamics === Dextromethorphan acts as an NMDA receptor antagonist, σ1 receptor agonist, and serotonin–norepinephrine reuptake inhibitor, among other actions, while bupropion acts as a norepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor negative allosteric modulator. Bupropion is also a potent inhibitor of CYP2D6, and thereby inhibits the metabolism of dextromethorphan. Dextromethorphan/bupropion has less activity as an NMDA receptor antagonist than dextromethorphan alone. This is because bupropion is a potent CYP2D6 inhibitor and prevents the bioactivation of dextromethorphan into dextrorphan, a much more potent NMDA receptor antagonist and weaker serotonin reuptake inhibitor than dextromethorphan itself. The mechanism of action of dextromethorphan/bupropion in the treatment of depression is unknown, although the preceding pharmacological actions are assumed to be involved.
== Publications == Eke has authored or co-authored over 200 peer-reviewed publications in leading journals, including The New England Journal of Medicine, Journal of the American Medical Association (JAMA), The Lancet, Clinical Infectious Diseases (CID), Clinical Pharmacology and Therapeutics, CPT Pharmacometrics and Systems Pharmacology, and the British Journal of Obstetrics and Gynecology. His published work has garnered over 7,800 citations, and spans topics such as perinatal pharmacology, maternal co-morbidities, and global health. In addition to original research, he has contributed expert commentaries and reviews, particularly in the fields of pharmacologic safety in pregnancy and maternal HIV care. His work is frequently cited in policy documents by organizations such as the American College of Obstetricians and Gynecologists (ACOG), the National Institute of Child Health and Human Development (NICHD), and the U.S. Food and Drug Administration (FDA).
Many of the characteristics of micelles differ from those of bulk solvents. For example, the micelles are, by nature, spatially heterogeneous with a hydrocarbon, nearly anhydrous core and a highly solvated, polar head group. They have a high surface-to-volume ratio due to their small size and generally spherical shape. Their surrounding environment (pH, ionic strength, buffer ion, presence of a co-solvent, and temperature) has an influence on their size, shape, critical micelle concentration, aggregation number and other properties. Another important property of micelles is the Krafft point, the temperature at which the solubility of the surfactant is equal to its CMC. For HPLC applications involving micelles, it is best to choose a surfactant with a low Krafft point and CMC. A high CMC would require a high concentration of surfactant which would increase the viscosity of the mobile phase, an undesirable condition. Additionally, a Krafft point should be well below room temperature to avoid having to apply heat to the mobile phase. To avoid potential interference with absorption detectors, a surfactant should also have a small molar absorptivity at the chosen wavelength of analysis. Light scattering should not be a concern due to the small size, a few nanometers, of the micelle. The effect of organic additives on micellar properties is another important consideration. A small amount of organic solvent is often added to the mobile phase to help improve efficiency and to improve separations of compounds. Care needs to be taken when determining how much organic to add.
Sources: en.wikipedia.org
=== Early radiation consequences === The discovery of X-rays by Wilhelm Conrad Röntgen (1845-1923) in 1895 led to extensive experimentation by scientists, physicians, and inventors. The first X-ray machines produced extremely unfavorable radiation spectra for imaging with extremely high skin doses. In February 1896, John Daniel and William Lofland Dudley (1859–1914) of Vanderbilt University conducted an experiment in which Dudley's head was X-rayed, resulting in hair loss. Herbert D. Hawks, a graduate of Columbia University, suffered severe burns on his hands and chest during demonstration experiments with X-rays. Burns and hair loss were reported in scientific journals. Nikola Tesla (1856–1943) was one of the first researchers to explicitly warn of the potential dangers of X-rays in the Electrical Review on May 5, 1897 - after initially claiming them to be completely harmless. He suffered massive radiation damage after his experiments. Nevertheless, some doctors at the time still claimed that X-rays had no effect on humans. Until the 1940s, X-ray machines were operated without any protective safeguards. Röntgen himself was spared the fate of the other X-ray users by habit. He always carried the unexposed photographic plates in his pockets and found that they were exposed if he remained in the same room during the exposure. So he regularly left the room when he took X-rays.
=== Primary and original calibrations === The agreed-upon isotopic composition of primary reference and the original calibration materials were generally not reached through interlaboratory comparison. In part this is simply because the original materials were used to the define the isotopic scales and so have no associated uncertainty. VSMOW serves as the primary reference and calibration material for the hydrogen isotope system and one of two possible scales for the oxygen isotope system, and was prepared by Harmon Craig. VSMOW2 is the replacement calibration standard and was calibrated by measurements at five selected laboratories. The isotopic composition of SLAP was reached through interlaboratory comparison. NBS-19 is the original calibration material for the carbon isotope scale made by I. Friedman, J. R. O’Neil and G. Cebula and is used to define the VPDB scale. IAEA-603 is the replacement calibration standard and was calibrated by measurements at three selected laboratories (GEOTOP-UQAM in Montreal, Canada; USGS in Reston, USA; MPI-BGC in Jena, Germany). The isotopic composition of LSVEC was reached through interlaboratory comparison. IAEA-S-1, the original calibration material for the sulfur isotope scale and still in use today, was prepared by B. W. Robinson.
=== Measurement in body fluids === Omeprazole may be quantified in plasma or serum to monitor therapy or to confirm a diagnosis of poisoning in hospitalized patients. Plasma omeprazole concentrations are usually in a range of 0.2–1.2 mg/L in persons receiving the drug therapeutically by the oral route and 1–6 mg/L in people with acute overdose. Enantiomeric chromatographic methods are available to distinguish esomeprazole from racemic omeprazole.
==== Women's international friendly matches ==== 22 February – China 0–0 Ireland. 8 April – USA 2–0 Ireland. 11 April – USA 1–0 Ireland. 22 June – Ireland 3–2 Zambia. 6 July – Ireland 0–3 France. 14 July – A friendly pre-World Cup warmup match against Colombia in Brisbane was abandoned after 20 minutes following harsh incidents by the South Americans against Denise O'Sullivan and Ruesha Littlejohn which earned the offenders yellow cards. O'Sullivan went to hospital with an injury inflicted by Colombian Daniela Caracas who said after the match that the Irish players "are little girls" ("Son unas nenas"), and "let them eat shit" ("que coman mierda").
=== Cyclodextrin (CD) chiral stationary phases === Cyclodextrin (CD) chiral stationary phase is produced by partial degradation of starch by the enzyme cyclodextrin glycosyltransferase, followed by enzymatic coupling of the glucose units, forming a toroidal structure. CDs are cyclic oligosaccharides consisting of six (α CDs), seven (β CDs) and eight (γ CDs) glucopyranose units. The chiral recognition mechanism is based on a sort of inclusion complexation. Complexation involves the interaction of the hydrophobic portion of an analyte enantiomer with the non-polar interior of the cavity, while the polar functional groups can form a hydrogen bond with the polar hydroxyl chiral cavity space. The most important factor that determines whether the analyte molecule will fit into the cyclodextrin cavity is its size. The α-CD consists of 30 stereo-selective centers, β-CD consists of 35 stereo-selective centers and γ-CD consists of 40 stereo-selective centers. When the hydrophobic portion of the analyte is larger or smaller than the toroid's cavity size, inclusion will not occur.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.